Currently, there are no effective treatments available to address the development and progression of IRDs, except for RPE65 gene therapy (Voretigene neparvovec-rzyl, Luxturna; Spark Therapeutics). This evidence concerns the gene RPE65 and respiratory distress syndrome in premature infants.